Literature DB >> 25337274

Expression of CD25 is a specific and relatively sensitive marker for the Philadelphia chromosome (BCR-ABL1) translocation in pediatric B acute lymphoblastic leukemia.

Amos S Gaikwad1, Rachel E Donohue2, M Tarek Elghetany3, Andrea M Sheehan3, Xinyan Y Lu4, Maria M Gramatges1, Kenneth L McClain1, Toni-Ann Mistretta3, Jyotinder N Punia3, Timothy J Moore5, Tatiana Goltsova5, Michael Cubbage5, Choladda V Curry3.   

Abstract

BACKGROUND: Precursor B acute lymphoblastic leukemia (B-ALL) is the most common cancer in children and overall, has an excellent prognosis. However, the Philadelphia chromosome translocation (Ph+), t(9;22)(q34;q11), is present in a small subset of patients and confers poor outcomes. CD25 (IL-2 receptor alpha chain) expression has been associated with Ph+ B-ALL in adults, but no similar study has been performed in pediatric B-ALL.
METHODS: A retrospective analysis of 221 consecutive pediatric patients with a diagnosis of B-ALL (blood and/or bone marrow) from 2009 to 2012 was performed to determine an association between Ph+ B-ALL and CD25 expression. A threshold of 25% was used to define positive cases for CD25 expression by flow cytometry.
RESULTS: There were 221 patients with a diagnosis of B-ALL ranging from 2 to 22 years (median, 6 years). Eight (3.6%) B-ALL patients were positive for the Philadelphia chromosome translocation (Ph+ B-ALL) and 213 were negative (Ph-negative B-ALL). CD25 expression was observed in 6 of 8 (75%) Ph+ B-ALL patients and 6 of 213 (2.8%) Ph-negative B-ALL patients. CD25 expression was significantly higher in Ph+ B-ALL compared to Ph-negative B-ALL, with median CD25 expression of 64% (range 0-93%) and 0.1% (range 0-91%), respectively (P ≤ 0.0002). Therefore, CD25 expression as a predictor of Ph+ B-ALL had 75% sensitivity, 97% specificity, 50% positive predictive value and 99% negative predictive value.
CONCLUSIONS: CD25 expression is a specific and relatively sensitive marker for the identification of Ph+ B-ALL in the pediatric population.

Entities:  

Keywords:  B acute lymphoblastic leukemia; B-ALL; BCR-ABL; CD25; Ph+; Ph+ B-ALL; Philadelphia chromosome; flow cytometry; pediatric; t(9;22)

Mesh:

Substances:

Year:  2014        PMID: 25337274      PMCID: PMC4203245     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  16 in total

Review 1.  Treatment of acute lymphoblastic leukemia.

Authors:  Ching-Hon Pui; William E Evans
Journal:  N Engl J Med       Date:  2006-01-12       Impact factor: 91.245

2.  Clinical and prognostic significance of cytokine receptor expression in adult acute lymphoblastic leukemia: interleukin-2 receptor alpha-chain predicts a poor prognosis.

Authors:  K Nakase; K Kita; H Miwa; K Nishii; M Shikami; I Tanaka; H Tsutani; T Ueda; K Nasu; T Kyo; H Dohy; H Shiku; N Katayama
Journal:  Leukemia       Date:  2007-01-04       Impact factor: 11.528

3.  Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia.

Authors:  Albert Moghrabi; Donna E Levy; Barbara Asselin; Ronald Barr; Luis Clavell; Craig Hurwitz; Yvan Samson; Marshall Schorin; Virginia K Dalton; Steven E Lipshultz; Donna S Neuberg; Richard D Gelber; Harvey J Cohen; Stephen E Sallan; Lewis B Silverman
Journal:  Blood       Date:  2006-09-26       Impact factor: 22.113

4.  Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95.

Authors:  Anja Möricke; Alfred Reiter; Martin Zimmermann; Helmut Gadner; Martin Stanulla; Michael Dördelmann; Lutz Löning; Rita Beier; Wolf-Dieter Ludwig; Richard Ratei; Jochen Harbott; Joachim Boos; Georg Mann; Felix Niggli; Andreas Feldges; Günter Henze; Karl Welte; Jörn-Dirk Beck; Thomas Klingebiel; Charlotte Niemeyer; Felix Zintl; Udo Bode; Christian Urban; Helmut Wehinger; Dietrich Niethammer; Hansjörg Riehm; Martin Schrappe
Journal:  Blood       Date:  2008-02-19       Impact factor: 22.113

5.  Expression of CD25 (interleukin-2 receptor alpha chain) in adult acute lymphoblastic leukemia predicts for the presence of BCR/ABL fusion transcripts: results of a preliminary laboratory analysis of ECOG/MRC Intergroup Study E2993. Eastern Cooperative Oncology Group/Medical Research Council.

Authors:  E Paietta; J Racevskis; D Neuberg; J M Rowe; A H Goldstone; P H Wiernik
Journal:  Leukemia       Date:  1997-11       Impact factor: 11.528

6.  Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia.

Authors:  Huimin Geng; Sarah Brennan; Thomas A Milne; Wei-Yi Chen; Yushan Li; Christian Hurtz; Soo-Mi Kweon; Lynette Zickl; Seyedmehdi Shojaee; Donna Neuberg; Chuanxin Huang; Debabrata Biswas; Yuan Xin; Janis Racevskis; Rhett P Ketterling; Selina M Luger; Hillard Lazarus; Martin S Tallman; Jacob M Rowe; Mark R Litzow; Monica L Guzman; C David Allis; Robert G Roeder; Markus Müschen; Elisabeth Paietta; Olivier Elemento; Ari M Melnick
Journal:  Cancer Discov       Date:  2012-10-29       Impact factor: 39.397

7.  Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004).

Authors:  Anjo J Veerman; Willem A Kamps; Henk van den Berg; Eva van den Berg; Jos P M Bökkerink; Marrie C A Bruin; Marry M van den Heuvel-Eibrink; Carin M Korbijn; Elisabeth T Korthof; Karin van der Pal; Theo Stijnen; Margreet H van Weel Sipman; J Fransje van Weerden; Elisabeth R van Wering; Anna van der Does-van den Berg
Journal:  Lancet Oncol       Date:  2009-09-09       Impact factor: 41.316

8.  Treating childhood acute lymphoblastic leukemia without cranial irradiation.

Authors:  Ching-Hon Pui; Dario Campana; Deqing Pei; W Paul Bowman; John T Sandlund; Sue C Kaste; Raul C Ribeiro; Jeffrey E Rubnitz; Susana C Raimondi; Mihaela Onciu; Elaine Coustan-Smith; Larry E Kun; Sima Jeha; Cheng Cheng; Scott C Howard; Vickey Simmons; Amy Bayles; Monika L Metzger; James M Boyett; Wing Leung; Rupert Handgretinger; James R Downing; William E Evans; Mary V Relling
Journal:  N Engl J Med       Date:  2009-06-25       Impact factor: 91.245

9.  Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:  M Aricò; M G Valsecchi; B Camitta; M Schrappe; J Chessells; A Baruchel; P Gaynon; L Silverman; G Janka-Schaub; W Kamps; C H Pui; G Masera
Journal:  N Engl J Med       Date:  2000-04-06       Impact factor: 91.245

10.  Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial.

Authors:  Anthony V Moorman; Christine J Harrison; Georgina A N Buck; Sue M Richards; Lorna M Secker-Walker; Mary Martineau; Gail H Vance; Athena M Cherry; Rodney R Higgins; Adele K Fielding; Letizia Foroni; Elisabeth Paietta; Martin S Tallman; Mark R Litzow; Peter H Wiernik; Jacob M Rowe; Anthony H Goldstone; Gordon W Dewald
Journal:  Blood       Date:  2006-12-14       Impact factor: 22.113

View more
  3 in total

Review 1.  Updates in the Pathology of Precursor Lymphoid Neoplasms in the Revised Fourth Edition of the WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues.

Authors:  Christopher Wenzinger; Eli Williams; Alejandro A Gru
Journal:  Curr Hematol Malig Rep       Date:  2018-08       Impact factor: 3.952

Review 2.  Common gamma chain cytokines in combinatorial immune strategies against cancer.

Authors:  Stephanie R Pulliam; Roman V Uzhachenko; Samuel E Adunyah; Anil Shanker
Journal:  Immunol Lett       Date:  2015-11-17       Impact factor: 3.685

Review 3.  Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?

Authors:  Axel Schulenburg; Katharina Blatt; Sabine Cerny-Reiterer; Irina Sadovnik; Harald Herrmann; Brigitte Marian; Thomas W Grunt; Christoph C Zielinski; Peter Valent
Journal:  J Hematol Oncol       Date:  2015-02-25       Impact factor: 17.388

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.